In The News
Vaxtracker wins NSW Health Keeping People Healthy Award
24 October 2023
Vaxtracker is thrilled to be the recipient of the NSW Health Award, in the Keeping People Healthy category. The Vaxtracker team has worked tirelessly since 2011 to provide active surveillance and monitor the safety of vaccines.
Vaxtracker grew rapidly during the COVID-19 pandemic, and provided national surveillance of the COVID-19 vaccines from the first roll-out. Vaxtracker's innovations have allowed rapid set-up of new surveillance programs, and we provided world-first safety data for the mpox Jynneos® vaccine within just two weeks.
Vaxtracker automates enrolment of participants in NSW-operated clinics to minimise patient burden, and also provides quick enrolment via QR codes in other clinics. To date, Vaxtracker has enrolled over 5 million participants to provide safety data to AVS and follow-up of adverse events following immunisation.
This award recognises our contribution to improving the health and wellbeing of Australians through innovation, and creating strong partnerships with States, Territories and Aboriginal Community Controlled Health Organisations.
Vaxtracker wins Hunter New England Keeping People Healthy Award
17 August 2023
Vaxtracker has been recognised at the Hunter New England Local Health District’s Excellence Awards, winning the Keeping People Healthy Award. This award highlights projects that take action to support people to make healthy choices, improve health outcomes for at-risk populations and prevent ill health.
Vaxtracker contributes world-first data for new vaccines with active surveillance, providing rapid confidence that they are effective and safe.
AusVaxSafety wins Research Australia Data Innovation Award
8 December 2022
AusVaxSafety, Australia’s active vaccine safety surveillance system, has been recognised at Research Australia’s 19th Health and Medical Research Awards, winning the Data Innovation Award. This award recognises their work in delivering nationally consistent vaccine safety surveillance in near-real time from the first day of the COVID-19 vaccine rollout, the largest and most complex immunisation program ever delivered in Australia.
The Data Innovation Award recognises innovative data collection, processing and analysis that advances health and medical research and is a testament to AusVaxSafety’s contribution to Australia’s robust vaccine safety monitoring system. Vaxtracker is one of the surveillance tools utilised by AusVaxSafety and plays an integral role in the surveillance of adverse events not just for COVID-19 vaccines but also routine childhood vaccinations, influenza, schools based vaccinations and more recently, mpox (monkeypox).
Vaxtracker would like to congratulate AusVaxSafety on this momentous win! We would also like to thank all of our partner agencies for their ongoing support and all of the individuals who have completed a vaccine safety survey through Vaxtracker.
Monkeypox vaccines safe and effective, Australian research finds
12 September 2022
Vaxtracker is facilitiating the world's first surveillance program for mpox vaccines. AusVaxSafety was the first world-wide to publish data from mpox vaccinations.
The data published by AusVaxSafety, and collected by Vaxtracker, has demonstrated that the vaccine is effective and safe.
Participants have reported a lower rate of reactions than both clinical trials for the mpox vaccine, and second doses of mRNA COVID-19 vaccines.
Vaxtracker wins National Immunisation Achievement Award
29 June 2021
The Public Health Association of Australia (PHAA) bestows the inaugural National Immunisation Achievement Award to honour and recognise outstanding service in the field of immunisation/vaccine preventable diseases.
This award is the pre-eminent prize in the field of immunisation/vaccine preventable diseases and is presented once every two years in conjunction with the PHAA National Immunisation Conference.
Patrick Cashman received the award for 2021, in recognition of the development of the Vaxtracker active safety surveillance platform, and other significant contributions in the field of vaccine safety.
Publications
2023
Deng L, Lopez LK, Glover C, Cashman P, Reynolds R, Macartney K, Wood N. Short-term adverse events following immunization with Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine for mpox. JAMA. Published online May 05, 2023. [Full text]
2022
Deng L, Glover C, Dymock M, Pillsbury A, Marsh JA, Quinn HE, Leeb A, Cashman P, Snelling TL, Wood N, Macartney K. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021. Med J Aust. 2022; 217(4):195-202. [Full text]
Thomas S, Durrheim D, Islam F, Higgins H, Cashman P. Improved immunization coverage using the World Health Organization's Tailoring Immunization Programmes guide (TIP) in a regional centre in Australia. Vaccine. 2022;40(1) [Abstract]
2021
Phillips A, Glover C, Leeb A, Cashman P, Fathima P, Crawford N, Snelling TL, Durrheim D, Macartney K. Safety of live attenuated herpes zoster vaccine in Australian adults 70–79 years of age: an observational study using active surveillance. BMJ Open. 2021;11(3) [Full text]
Thomas S, Allan N, Taylor P, McGrady C, Bolsewicz K, Islam F, Cashman P, Durrheim D, Creighton A. Combining First Nations Research Methods with a World Health Organization Guide to Understand Low Childhood Immunisation Coverage in Children in Tamworth, Australia. The International Indigenous Policy Journal. 2021;12(2) [Full text]
2020
Cashman, P., Munnoch, S., Clark, K., Allan, N., Clarke, S., Macartney, K., & Durrheim, D. (2020). The Aboriginal gap in online active vaccine safety surveillance. Australian Indigenous HealthBulletin. 2020 1;(1). [Full text]
Pillsbury A, Fathima P, Quinn HE, Cashman P, Blyth CC, Leeb A, Macartney K. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older. JAMA Network Open. 2020;3(5) [Full text]
2019
Munnoch S, Cashman P, Peel R, Attia J, Hure A, Durrheim D. Participant-Centered Online Active Surveillance for Adverse Events Following Vaccination in a Large Clinical Trial: Feasibility and Usability Study. Journal of Medical Internet Research. 2019;21(10) [Full text]
Cashman P, Moberley S, Chee K, Stephenson J, Chaverot S, Martinelli J, Gadsden T, Bateman-Steel C, Redwood L, Howard Z, Ferson MJ, Durrheim DN. Participant centred safety surveillance of health care workers receiving influenza vaccination. Vaccine. 2019;37(18):2427–2429 [Abstract]
Thomas S, Higgins H, Leask J, Menning L, Habersaat K, Massey P, Taylor K, Cashman P, Durrheim DN. Improving child immunisation rates in a disadvantaged community in New South Wales, Australia: a process evaluation for research translation. Australian journal of Primary Health. 2019;25(4) [Abstract]
2018
Pillsbury AJ, Glover C, Jacoby P, Quinn HE, Fathima P, Cashman P, Leeb A, Blyth CC, Gold MS, Snelling T, Macartney K. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia. BMJ Open. 2018;8(10) [Full text]
Thomas S, Cashman P, Islam F, Baker L, Clark K, Leask J, Butler R, Durrheim DN. Tailoring immunisation service delivery in a disadvantaged community in Australia; views of health providers and parents. Vaccine. 2018;36(19) [Abstract]
2017
Cashman P, Macartney K, Khandaker G, King C, Gold M, Durrheim DN. Participant-centred active surveillance of adverse events following immunisation: a narrative review. International Health. 2017; 9(3) [Full text]
Pilsbury A, Quinn H, Cashman P, Leeb A, Macartney K on behalf of the AusVAxSafety consortium. Active SMS-based influenza vaccine safety surveillance in Australian Children. Vaccine. 2017;35(51) [Abstract]
2016
Cashman PM, Allan NA, Clark KK, Butler M, Massey P, Durrheim D. Closing the gap in Australian Aboriginal infant immunisation rates – the development and review of a pre-call strategy. BMC Public Health. 2016;16 [Full text]
Staples S, Butler M, Nguyen, Durrheim DN, Cashman P, Brotherton JML. Opportunities to increase rates of human papillomavirus vaccination in the New South Wales school program through enhanced catch-up. Sexual Health. 2016;13(6) [Abstract]
2015
Pillsbury A, Cashman P, Leeb A, Regan A, Westphal D, Snelling T, Blyth C, Crawford N, Wood N, Macartney K, on behalf of the AusVaxSafety surveillance team. Real-time safety surveillance of seasonal influenza vaccines in children, Australia. Euro Surveillance. 2015;20(43) [Full text]
2014
Cashman P, Moberley S, Dalton C, Stephenson J, Elvidge E, Butler M, Durrheim, D. Vaxtracker: Active on-line surveillance for adverse events following inactivated influenza vaccine in children. Vaccine. 2014;32(42) [Full text]
2012
Hope K, Butler M, Massey PD, Cashman P, Durrheim DN, Stephenson J, Worley A. Pertussis vaccination in Child Care Workers: room for improvement in coverage, policy and practice. BMC Pediatrics. 2012;12 [Full text]
Wood N, Sheppeard V, Cashman P, Palasanthiran P, Casacelli M, Mcintyre P. Influenza vaccine safety in children less than 5 years old the 2010 and 2011 experience in Australia. The Pediatric Infectious Disease Journal. 2012;31(2) [Full text]
Berling I, Stephenson J, Cashman P, Loten C, Butler M, Durrheim D. Opportunistic childhood vaccinations in emergency – Are we really missing anyone?. Australasian Emergency Nursing Journal. 2012;15(1) [Abstract]
2011
Allan N, Cashman P. Aboriginal identification in Hunter New England infants. NSW Public Health Bulletin. 2011;22(11-12) [Full text]
Wood NJ, Cashman PM. Influenza immunisation program at three tertiary paediatric hospitals in NSW in 2010. NSW Public Health Bulletin. 2011;22(11–12) [Full text]
2010
Durrheim D, Cashman P. Addressing the immunization coverage paradox: A matter of children's rights and social justice. Clinical Therapeutics. 2010;32(8) [Abstract]
Last Updated: 8/02/24